AlphAIAlphAI — Financial news for AI agents
marketscreener.comOCT 141 min read$A

JPMorgan Adjusts Price Target on Agilent Technologies to $195 From $190

JPMorgan raised its price target for Agilent Technologies to $195 from $190. UBS also increased its target to $180 from $165. Agilent's stock is up 1.34% year-to-date and 26.11% over 5 days.

Original reporting
marketscreener.com
Published Oct 14, 2026, 10:41 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 10:58 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$A
Bullish
high confidence
Mentioned
$A
Relevance
7/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$ABullishMed
01

Why it matters

The upgrade may attract short‑term buying, but the effect depends on broader market sentiment and upcoming earnings.

02

Market read

Analyst target change provides a modest trading signal for Agilent, with limited broader market impact.

03

What to watch

Upcoming earnings guidance and competitive pressures could offset the target increase.

Relevance 7/10Novelty 6/10Timing: pre‑market today

Background

JPMorgan's research team adjusted its valuation assumptions for Agilent Technologies, resulting in a higher price target.

Company-level read

Ticker impact

$ABullishHigh confidence
Context

JPMorgan raised Agilent Technologies' price target to $195 from $190.

Expected impact

likely modest upward pressure as investors price in the higher target

Evidence & confidence

Target raise reflects improved earnings visibility and valuation, prompting buying interest.

Market effects

Sector

May lift sentiment in the life‑sciences instrumentation sector.

Regional

Limited to U.S. markets where Agilent trades.

Global

Minimal global impact beyond sector peers.

Counterpoint

What could challenge this read

Target raises can be premature if based on optimistic forecasts; price may stall.

Key entities

  • company
    Agilent Technologies

    US‑listed life‑sciences instrumentation firm (ticker A).

  • analyst_firm
    JPMorgan

    Investment bank providing the price‑target revision.

Read at source← All news

Related articles

OCT 18
$AHighAI 9/10

Philadelphia's Proscia to Sell to Agilent for Up to $270M

Agilent Technologies (NYSE: A) agreed to acquire Proscia, a digital pathology software company, for up to $270M. The deal includes $240M upfront and $30M in performance-based payments. Proscia's software integrates AI tools and manages digital tissue images, serving over 4,000 labs and 16 top pharmaceutical firms. The acquisition aims to expand Agilent's presence in the $5B pathology market, combining its diagnostic instruments with Proscia's software.

mychesco.com2 min
OCT 18
$AHighAI 9/10

Philadelphia AI Cancer Diagnostics Firm Proscia Acquired for Up to $270M

Agilent Technologies (A) is acquiring Proscia, an AI cancer diagnostics firm, for up to $270M ($240M in cash, $30M in milestones). Proscia's software digitizes tissue samples for AI analysis, used by 4,000 labs and 16 top pharma companies. The deal expands Agilent's presence in digital pathology. Proscia will remain in Philadelphia, with the deal expected to close in early fiscal 2027.

philadelphia.today2 min
OCT 18
$AHighAI 9/10

Agilent Agrees to Buy Proscia for $240M

Agilent Technologies agreed to acquire Proscia for $240M in cash, with up to $30M more tied to performance milestones. Proscia's trailing revenue exceeded $18M. The deal will integrate Proscia's digital pathology software into Agilent's business, expected to close in early fiscal 2027.

quasa.io2 min
OCT 16
$BMBLHighAI 9/10

Deal Dispatch: Ithaca Holdings Buys Bumble for $1.3B, The Knot Acquires Zola, Character.ai Bankruptcy

Bumble (BMBL) agreed to a $1.3B all-cash acquisition by Ithaca Holdings, becoming privately held. IonQ will acquire Elisity in an all-stock deal up to $1.3B. Agilent (A) to buy Proscia for $240M. Workday (WDAY) acquiring C1.ai. Aurora Cannabis exploring alternatives to Curaleaf's bid. Character.ai filed for bankruptcy, Disney to pay $20M for IP. Getty Images plans Chapter 11, going private with Koch backing.

finance.yahoo.com3 min
OCT 14
$AHighAI 9/10

Agilent acquires Proscia in deal worth up to $270m

Agilent (A) will acquire Proscia for up to $270m, including $240m upfront and $30m for performance milestones. The deal aims to enhance Agilent's pathology portfolio with Proscia's digital pathology software, Concentriq Dx, which has FDA clearance. Proscia serves over 4,000 labs and 16 top pharma companies, according to Agilent. The acquisition is expected to close in Agilent's fiscal year 2027.

finance.yahoo.com2 min